Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.93 |
---|---|
High | 7.66 |
Low | 6.85 |
Bid | 7.00 |
Offer | 7.36 |
Previous close | 7.00 |
Average volume | 190.09k |
---|---|
Shares outstanding | 25.84m |
Free float | 24.44m |
P/E (TTM) | -- |
Market cap | 180.85m USD |
EPS (TTM) | -0.2596 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 21:00 BST.
More ▼
Announcements
- Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
- Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
- Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
- Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
- Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
- Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
- Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
- Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
- Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
More ▼